About Inovio Pharmaceuticals
Inovio Pharmaceuticals is a company based in Plymouth Meeting (United States) founded in 1983 by Joseph Kim. The company has 134 employees as of December 31, 2024. Inovio Pharmaceuticals has completed 2 acquisitions, including Bioject and VGX Pharmaceuticals. Inovio Pharmaceuticals offers products and services including DNA Medicines and CELLECTRA Devices. Inovio Pharmaceuticals operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Plymouth Meeting, United States
- Employees 134 as on 31 Dec, 2024
- Founders Joseph Kim
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inovio Pharmaceuticals, Inc.
-
Annual Revenue
$217.76 K (USD)-73.83as on Dec 31, 2024
-
Net Profit
-$107.25 M (USD)20.62as on Dec 31, 2024
-
EBITDA
-$110.87 M (USD)15.83as on Dec 31, 2024
-
Latest Funding Round
$37.6 M (USD), Grant
Dec 16, 2020
-
Investors
NIH
& 8 more
-
Employee Count
134
as on Dec 31, 2024
-
Investments & Acquisitions
Bioject
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Inovio Pharmaceuticals
Inovio Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol INO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Inovio Pharmaceuticals
Inovio Pharmaceuticals offers a comprehensive portfolio of products and services, including DNA Medicines and CELLECTRA Devices.
Plasmids that enable cells to produce proteins against diseases
Devices for delivering DNA plasmids into cells effectively
People of Inovio Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Inovio Pharmaceuticals
Investors in Inovio Pharmaceuticals
Inovio Pharmaceuticals has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Korea Investment Holdings and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Locked | Locked | Locked | |
|
Investment holding firm established in Seoul in 2003.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Inovio Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inovio Pharmaceuticals
Inovio Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bioject and VGX Pharmaceuticals.
Investment portfolio details for Inovio Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
DNA-based vaccines for infectious diseases and cancers are developed.
|
Locked | Locked | 2002 | Locked | |
|
Needle-free injection therapies are developed for medical drug delivery.
|
Locked | Locked | 1985 | Locked |
Complete acquisition details for Inovio Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Inovio Pharmaceuticals
Detailed financials for Inovio Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inovio Pharmaceuticals Comparisons
Peer comparison for Inovio Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inovio Pharmaceuticals
Inovio Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of Inovio Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inovio Pharmaceuticals
Complete news archive for Inovio Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inovio Pharmaceuticals
Inovio Pharmaceuticals was founded in 1983 and raised its 1st funding round 19 years after it was founded.
Inovio Pharmaceuticals is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Joseph Kim is the current CEO of Inovio Pharmaceuticals. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Inovio Pharmaceuticals is 134.
Annual revenue of Inovio Pharmaceuticals is $217.76K as on Dec 31, 2024.
Founded in 1983 and based in Plymouth Meeting, United States, Inovio Pharmaceuticals operates in the biotechnology sector. Synthetic DNA vaccines are developed, delivered via proprietary electroporation to elicit antibody and T-cell responses. The pipeline encompasses immunotherapies targeting cancers of the cervix, head and neck, prostate, breast, lung, and pancreas, alongside protections against infectious diseases including hepatitis, HIV, Ebola, and MERS.
Inovio Pharmaceuticals's top competitors include Moderna, BeiGene and Strand Therapeutics.
Inovio Pharmaceuticals offers DNA Medicines and CELLECTRA Devices.
Yes, Inovio Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol INO.
Inovio Pharmaceuticals has made 2 acquisitions, including Bioject, and VGX Pharmaceuticals.
Inovio Pharmaceuticals has 9 investors. Key investors include NIH, Korea Investment Holdings, Gates Foundation, DARPA, and CEPI.
The ticker symbol of Inovio Pharmaceuticals is INO on NASDAQ.